Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Novavax Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $78.96, while Novavax Inc trades at $7.93 (market cap $1.33B). The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| IEMG | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $11.19 |
52-Week Low | $59.90 | $6.22 |
Market Cap | — | $1.33B |
Enterprise Value | — | $832.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal. The ETF shows strong recent performance with 35% one-year returns but faces elevated volatility. Technical indicators show oversold conditions with RSI at 24.55, while moving averages signal bearish momentum. Recent news highlights record inflows into emerging markets and IEMG's 40% technology weighting, particularly in South Korean and Taiwanese semiconductor stocks.
IEMG offers exposure to emerging markets at attractive valuations but carries higher volatility than developed market ETFs. The AI-driven tech concentration provides growth potential but increases sensitivity to sector rotations. Key risks include geopolitical tensions and currency fluctuations, while the low 0.09% expense ratio maintains cost efficiency for long-term investors.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
